Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

NCT00081939 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT00081939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
September 30, 2014
Enrollment
303 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma